tbuckley/cabot-search huggingface dataset:
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma
Authors: Rahul Suresh, David J Barakat, Theresa Barberi, Lei Zheng, Elizabeth Jaffee, Kenneth J Pienta, Alan D Friedman
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma grow slower in p50 −/ − mice. We therefore evaluated the efficacy of p50-negative immature myeloid cells (p50-IMCs) adoptively transferred into tumor-bearing hosts. Immature cells were used to maximize tumor localization, and pretreatment with 5-fluorouracil (5FU) was examined due to its potential to impair marrow production of myeloid cells, to target tumor myeloid cells and to release tumor neoantigens. Methods Wild-type (WT)-IMC or p50-IMC were generated by culturing lineage-negative marrow cells from WT or p50 −/ − mice in media containing thrombopoietin, stem cell factor and Flt3 ligand for 6 days followed by monocyte colony-stimulating factor for 1 day on ultralow attachment plates. Mice inoculated with Hi-Myc prostate cancer (PCa) cells or K-Ras G12D pancreatic ductal carcinoma (PDC)-luciferase cells received 5FU followed 5 days later by three doses of 10 7 immature myeloid cells (IMC) every 3–4 days. Results PCa cells grew slower in p50 −/ − mice, and absence of host p50 prolonged the survival of mice inoculated orthotopically with PDC cells. IMC from Cytomegalovirus (CMV)-luciferase mice localized to tumor, nodes, spleen, marrow, and lung. 5FU followed by p50-IMC slowed PCa and PDC tumor growth, ~3-fold on average, in contrast to 5FU followed by WT-IMC, 5FU alone or p50-IMC alone. Slowed tumor growth was evident for 93% of PCa but only 53% of PDC tumors; we therefore focused on PCa for additional IMC analyses. In PCa, p50-IMC matured into F4/80 + macrophages, as well as CD11b + F4/80 − CD11c + conventional dendritic cells (cDCs). In both tumor and draining lymph nodes, p50-IMC generated more macrophages and cDCs than WT-IMC. Activated tumor CD8 + T cells were increased fivefold by p50-IMC compared with WT-IMC, and antibody-mediated CD8 + T cell depletion obviated slower tumor growth induced by 5FU followed by p50-IMC. Conclusions 5FU followed by p50-IMC slows the growth of murine prostate and pancreatic carcinoma and depends on CD8 + T cell activation. Deletion of p50 in patient-derived marrow CD34 + cells and subsequent production of IMC for adoptive transfer may contribute to the therapy of these and additional cancers.
Continuous pre- and post-transplant exposure to a disease-associated gut microbiome promotes hyper-acute graft-versus-host disease in wild-type mice
Authors: Kate L Bowerman, Antiopi Varelias, Nancy Lachner, Rachel D Kuns, Geoffrey R Hill, Philip Hugenholtz
Journal: Gut Microbes (2020)

Objective The gut microbiome plays a key role in the development of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. Here we investigate the individual contribution of the pre- and post-transplant gut microbiome to acute GVHD using a well-studied mouse model.Design Wild-type mice were cohoused with IL-17RA–/ – mice, susceptible to hyperacute GVHD, either pre- or post-transplant alone or continuously (i.e., pre- and post-transplant). Fecal samples were collected from both WT and IL-17RA–/ – mice pre- and post-cohousing and post-transplant and the microbiome analyzed using metagenomic sequencing.Results Priming wild-type mice via cohousing pre-transplant only is insufficient to accelerate GVHD, however, accelerated disease is observed in WT mice cohoused post-transplant only. When mice are cohoused continuously, the effect of priming and exacerbation is additive, resulting in a greater acceleration of disease in WT mice beyond that seen with cohousing post-transplant only. Metagenomic analysis of the microbiome revealed pre-transplant cohousing is associated with the transfer of specific species within two as-yet-uncultured genera of the bacterial family Muribaculaceae; CAG-485 and CAG-873. Post-transplant, we observed GVHD-associated blooms of Enterobacteriaceae members Escherichia coli and Enterobacter hormaechei subsp. steigerwaltii, and hyperacute GVHD gut microbiome distinct from that associated with delayed-onset disease (>10 days post-transplant).Conclusion These results clarify the importance of the peri-transplant microbiome in the susceptibility to acute GVHD post-transplant and demonstrate the species-specific nature of this association.
Infant Mortality Attributable to Birth Defects — United States, 2003–2017
Authors: Lynn M. Almli, Danielle M. Ely, Elizabeth C. Ailes, Rahi Abouk, Scott D. Grosse, Jennifer L. Isenburg, Debra B. Waldron, Jennita Reefhuis
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Birth defects are a leading cause of infant mortality in the United States, accounting for 20.6% of infant deaths in 2017 (1). Rates of infant mortality attributable to birth defects (IMBD) have generally declined since the 1970s (1-3). U.S. linked birth/infant death data from 2003-2017 were used to assess trends in IMBD. Overall, rates declined 10% during 2003-2017, but decreases varied by maternal and infant characteristics. During 2003-2017, IMBD rates decreased 4% for infants of Hispanic mothers, 11% for infants of non-Hispanic black (black) mothers, and 12% for infants of non-Hispanic white (white) mothers. In 2017, these rates were highest among infants of black mothers (13.3 per 10,000 live births) and were lowest among infants of white mothers (9.9). During 2003-2017, IMBD rates for infants who were born extremely preterm (20-27 completed gestational weeks), full term (39-40 weeks), and late term/postterm (41-44 weeks) declined 20%-29%; rates for moderate (32-33 weeks) and late preterm (34-36 weeks) infants increased 17%. Continued tracking of IMBD rates can help identify areas where efforts to reduce IMBD are needed, such as among infants born to black and Hispanic mothers and those born moderate and late preterm (32-36 weeks).
A Phase I/II Study of BI-Weekly Xeliri Plus Bevacizumab for Patient with Metastatic Colorectal Cancer as Second-Line Chemotherapy (Bixer Study): Reports of Interim Analysis of Phase II Part
Authors: M. Suenaga, S. Matsusaka, E. Shinozaki, M. Ozaka, M. Ogura, K. Chin, K. Hatake, N. Mizunuma, T. Yamaguchi
Journal: Annals of Oncology (2012)
Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T
Authors: Alberto Aimo, James L. Januzzi, Giuseppe Vergaro, A. Mark Richards, Carolyn S.P. Lam, Roberto Latini, Inder S. Anand, Jay N. Cohn, Thor Ueland, Lars Gullestad, Pål Aukrust, Hans‐Peter Brunner‐La Rocca, Antoni Bayes‐Genis, Josep Lupón, Rudolf A. de Boer, Yasuchika Takeishi, Michael Egstrup, Ida Gustafsson, Hanna K. Gaggin, Kai M. Eggers, Kurt Huber, Greg D. Gamble, Lieng H. Ling, Kui Tong Gerard Leong, Poh Shuah Daniel Yeo, Hean Yee Ong, Fazlur Jaufeerally, Tze P. Ng, Richard Troughton, Robert N. Doughty, Claudio Passino, Michele Emdin
Journal: European Journal of Heart Failure (2020)
Safety of Cytotoxic Chemotherapy Following Radium-223 Chloride (RA-223) Therapy in the Phase 3 Alsympca Study in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
Authors: O. Sartor, R.E. Coleman, S. Nilsson, N. Vogelzang, A. Cross, C.G. O'Bryan-Tear, K. Staudacher, J.E. Garcia-Vargas, J. Zou, C. Parker
Journal: Annals of Oncology (2012)
Circulating Tumor Cells and T790M in Metastatic Non-Small-Cell Lung Cancer Patients with EGFR Mutations and Acquired Resistance to TKI
Authors: K. Isobe, Y. Hata, N. Hirota, G. Sano, K. Sato, K. Sugino, S. Sakamoto, Y. Takai, K. Shibuya, K. Takagi, S. Homma
Journal: Annals of Oncology (2012)
Healthcare Associated Infections in Head and Neck Carcinoma Patients Treated with Chemotherapy and/or Radiotherapy
Authors: A. Mirabile, C. Vismara, P. Bossi, L. Locati, C. Bergamini, R. Granata, C. Resteghini, D. Morelli, P. Scarpellini, L. Licitra
Journal: Annals of Oncology (2012)
Palliative Care Use in Patients With Acute Myocardial Infarction
Authors: Islam Y Elgendy, Ayman Elbadawi, Partha Sardar, Dhaval Kolte, Mohamed A Omer, Ahmed N Mahmoud, Hani Jneid, Ellen C Keeley, Deepak L Bhatt
Journal: Journal of the American College of Cardiology (2020)
P-0295 Anorectal Melanomas In Department of Medical Oncology, Hassan II University Hospital, Morocco
Authors: Karima Oualla, Fatima Zahra El M'rabet, Zineb Benbrahim, Nezar Bouyahia, Sami Aziz Brahmi, Samia Arifi, Nawfel Mellas, Omar El Mesbahi
Journal: Annals of Oncology (2012)
Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology
Authors: Wilfried Mullens, Kevin Damman, Jeffrey M. Testani, Pieter Martens, Christian Mueller, Johan Lassus, W.H. Wilson Tang, Hadi Skouri, Frederik H. Verbrugge, Francesco Orso, Loreena Hill, Dilek Ural, Mitcha Lainscak, Patrick Rossignol, Marco Metra, Alexandre Mebazaa, Petar Seferovic, Frank Ruschitzka, Andrew Coats
Journal: European Journal of Heart Failure (2020)
Corrections to “Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines”
Authors: S. Roselló, I. Blasco, L. García Fabregat, A. Cervantes, K. Jordan
Journal: Annals of Oncology (2018)

Ann Oncol 2017; 28: iv100–iv118 (doi:10.1093/annonc/mdx216) In “Table 6. Characteristics and management of IRs with some monoclonal antibodies” (row 6, column 4) 90% on the first infusion. Severe 2%–5% Is replaced with: Incidence of IR 7-10%. Severe IR in 2-5%, 90% of which occur in the first infusion. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice GuidelinesAnnals of OncologyVol. 28PreviewMost anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. Severe reactions are less frequent and may be fatal without appropriate intervention. Full-Text PDF Open Archive
Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)
Authors: R. Rosell, B. Massuti Sureda, C. Costa, M.A. Molina, A. Gimenez-Capitan, N. Karachaliou, J. Wei, A. Vergnenegre, P. Giannikopoulos, C. Mermel, T. Bivona, F. De Marinis, E. Felip, T. Moran Bueno, R. Gervais, M. Santarpia, M. Majem, J. Bosch-Barrera, M.R. Garcia-Campelo, L. Paz-Ares
Journal: Annals of Oncology (2012)
Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression
Authors: S. Oudard, S. Culine, A. Vieillefond, F. Priou, F. Goldwasser, A. Ravaud, G. Gravis-Mescam, G. Deplanque, J.P. Machiels, P. Beuzeboc
Journal: Annals of Oncology (2012)
Adverse Events (AES) Associated with Bevacizumab (BV) In Older Patients (PTS) With Metastatic Colorectal Cancer (MCRC)
Authors: V. Shankaran, D. Mummy, L. Koepl, D. Blough, Y.M. Yim, E. Yu, S. Ramsey
Journal: Annals of Oncology (2012)
Potential gains in life expectancy by attaining daily ambient fine particulate matter pollution standards in mainland China: A modeling study based on nationwide data
Authors: Jinlei Qi, Zengliang Ruan, Zhengmin (Min) Qian, Peng Yin, Yin Yang, Bipin Kumar Acharya, Lijun Wang, Hualiang Lin
Journal: PLoS Medicine (2020)

Background Ambient fine particulate matter pollution (PM2.5) is one leading cause of disease burden, but no study has quantified the association between daily PM2.5 exposure and life expectancy. We aimed to assess the potential benefits in life expectancy by attaining the daily PM2.5 standards in 72 cities of China during 2013–2016. Methods and findings We applied a two-stage approach for the analysis. At the first stage, we used a generalized additive model (GAM) with a Gaussian link to examine the city-specific short-term association between daily PM2.5 and years of life lost (YLL); at the second stage, a random-effects meta-analysis was used to generate the regional and national estimations. We further estimated the potential gains in life expectancy (PGLE) by assuming that ambient PM2.5 has met the Chinese National Ambient Air Quality Standard (NAAQS, 75 μg/m3) or the ambient air quality guideline (AQG) of the World Health Organization (WHO) (25 μg/m3). We also calculated the attributable fraction (AF), which denoted the proportion of YLL attributable to a higher-than-standards daily mean PM2.5 concentration. During the period from January 18, 2013 to December 31, 2016, we recorded 1,226,849 nonaccidental deaths in the study area. We observed significant associations between daily PM2.5 and YLL: each 10 μg/m3 increase in three-day–averaged (lag02) PM2.5 concentrations corresponded to an increment of 0.43 years of life lost (95% CI: 0.29–0.57). We estimated that 168,065.18 (95% CI: 114,144.91–221,985.45) and 68,684.95 (95% CI: 46,648.79–90,721.11) years of life lost can be avoided by achieving WHO's AQG and Chinese NAAQS in the study area, which corresponded to 0.14 (95% CI: 0.09–0.18) and 0.06 (95% CI: 0.04–0.07) years of gain in life expectancy for each death in these cities. We observed differential regional estimates across the 7 regions, with the highest gains in the Northwest region (0.28 years of gain [95% CI: 0.06–0.49]) and the lowest in the North region (0.08 [95% CI: 0.02–0.15]). Furthermore, using WHO's AQG and Chinese NAAQS as the references, we estimated that 1.00% (95% CI: 0.68%–1.32%) and 0.41% (95% CI: 0.28%–0.54%) of YLL could be attributable to the PM2.5 exposure at the national level. Findings from this study were mainly limited by the unavailability of data on individual PM2.5 exposure. Conclusions This study indicates that significantly longer life expectancy could be achieved by a reduction in the ambient PM2.5 concentrations. It also highlights the need to formulate a stricter ambient PM2.5 standard at both national and regional levels of China to protect the population's health.
Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling
Authors: Yuhu He, Caojian Zuo, Daile Jia, Peiyuan Bai, Deping Kong, Di Chen, Guizhu Liu, Juanjuan Li, Yuanyang Wang, Guilin Chen, Shuai Yan, Bing Xiao, Jian Zhang, Lingjuan Piao, Yanli Li, Yi Deng, Bin Li, Philippe P. Roux, Katrin I. Andreasson, Richard M. Breyer, Yunchao Su, Jian Wang, Ankang Lyu, Yujun Shen, Ying Yu
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Vascular remodeling, including smooth muscle cell hypertrophy and proliferation, is the key pathological feature of pulmonary arterial hypertension (PAH). Prostaglandin I2 analogs (beraprost, iloprost, and treprostinil) are effective in the treatment of PAH. Of note, the clinically favorable effects of treprostinil in severe PAH may be attributable to concomitant activation of DP1 (D prostanoid receptor subtype 1).Objectives: To study the role of DP1 in the progression of PAH and its underlying mechanism.Methods: DP1 levels were examined in pulmonary arteries of patients and animals with PAH. Multiple genetic and pharmacologic approaches were used to investigate DP1-mediated signaling in PAH.Measurements and Main Results: DP1 expression was downregulated in hypoxia-treated pulmonary artery smooth muscle cells and in pulmonary arteries from rodent PAH models and patients with idiopathic PAH. DP1 deletion exacerbated pulmonary artery remodeling in hypoxia-induced PAH, whereas pharmacological activation or forced expression of the DP1 receptor had the opposite effect in different rodent models. DP1 deficiency promoted pulmonary artery smooth muscle cell hypertrophy and proliferation in response to hypoxia via induction of mTORC1 (mammalian target of rapamycin complex 1) activity. Rapamycin, an inhibitor of mTORC1, alleviated the hypoxia-induced exacerbation of PAH in DP1-knockout mice. DP1 activation facilitated raptor dissociation from mTORC1 and suppressed mTORC1 activity through PKA (protein kinase A)-dependent phosphorylation of raptor at Ser791. Moreover, treprostinil treatment blocked the progression of hypoxia-induced PAH in mice in part by targeting the DP1 receptor.Conclusions: DP1 activation attenuates hypoxia-induced pulmonary artery remodeling and PAH through PKA-mediated dissociation of raptor from mTORC1. These results suggest that the DP1 receptor may serve as a therapeutic target for the management of PAH.
P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer
Authors: S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravergna, K. Bencardino, A. Cercek, C. Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, V. Boscaro, E. Medico, M. Weiser, S. Siena, F. di Nicolantonio, D. Solit, A. Bardelli
Journal: Annals of Oncology (2012)
Crepitus and Subcutaneous Emphysema
Authors: Yehia Saleh, Ahmad Alratroot
Journal: New England Journal of Medicine (2020)

An 86-year-old woman with a history of severe emphysema presented with shortness of breath. The physical examination revealed diminished breath sounds in the right hemithorax and extensive subcutaneous emphysema, with palpable crepitus in the neck (shown in a video).
Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis
Authors: Andre C. Kalil
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Item Response Theory and Factor Analysis as Mean to Characterize Occurrence of Response Shift for Longitudinal Quality of Life Study in Breast Cancer Patients
Authors: A. Anota, C. Bascoul-Mollevi, F. Guillemin, T. Conroy, M. Velten, D. Jolly, M. Mercier, S. Causeret, T.S. Dabakuyo, F. Bonnetain
Journal: Annals of Oncology (2012)
Resistant behaviour in dementia might be due to hearing loss
Authors: Ted Leverton
Journal: BMJ (2020)

Cook and colleagues summarise many deficiencies in the care of people with dementia but do not mention hearing loss or deafness.1

How can I follow instructions if I can’t hear what you are saying? In the paper they summarise, by Featherstone et al, resistant behaviour is discussed as though it is a failure on the part of the patient.2 In my experience, the failure is often that the …
Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial
Authors: J. Taieb, J. Tabernero, E. Mini, F. Subtil, G. Folprecht, J. Van Laethem, J. Thaler, J.A. Bridgewater, E.J.D. Van Cutsem, P. Rougier, L. Collette, M. Praet, M. Schneider, O. Bouché, C. Lepage, C. Girault, J.F. Emile, P. Laurent-Puig, L. Bedenne
Journal: Annals of Oncology (2012)
Efficacy and Safety of Two Neoadjuvant Strategies with Bevacizumab in Locally Advanced Resectable Rectal Cancer: Interim Results of a Randomized, Non-Comparative Phase II Study
Authors: J. Bosset, G. Mantion, T. André, F. Boudghène, F. Piard, F. Mornex, P. Maingon, A. Adenis, M. Piutti, C. Borg
Journal: Annals of Oncology (2012)
Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)
Authors: S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, M.W. Lu, S. Olsen, K. Blackwell
Journal: Annals of Oncology (2012)
Observational Crossover Study of Cabazitaxel and Abiraterone Acetate in Metastatic Docetaxel-Refractory Castration-Resistant Prostate Cancer (MDR-CRPC)
Authors: S. Bracarda, M. Sisani, A. Hamzaj, F. Marrocolo, S. Del Buono, V. De Angelis
Journal: Annals of Oncology (2012)
Effect of young age (&lt;50) on clinical, pathologic features and survival of patients with colorectal cancer.
Authors: Jamal Zidan, Jehad Abu Salah, Adi Sharabi-Nov
Journal: Journal of Clinical Oncology (2012)

e14025 Background: Colorectal cancer is one of the most common malignancies in both men and women in Israel. Most patients with colon cancer are older than 50 years of age. However young patients are not rare. There is no consensus in the literature regarding the behavior of this disease in young patients. Clinical and pathological characteristics of colon cancer patients treated at Oncology Institute in Ziv Medical Center were retrospectively analyzed. The aim of the present study is to compare clinical and pathological features of colon cancer between young and old patients. Methods: A total of 200 patients with colon cancer were treated at our institute during 8 years. Twenty five (12.5%) of them were &lt;50 years age (young patients) at diagnosis. All clinical and pathological characteristics were taken retrospectively from the hospital files. In situations where the pathological findings were not noted in the chart, review of the stored tumor was requested from the pathology department. Acceptable statistical methods were used for statistical calculations. Results: Among the 200 patients 25 (12.5%) were &lt;50 years age at diagnosis (mean age 41 years) and 175 were &gt;50 years (mean age 70 years). Males were 56% of the young group and 60.1% of the old one. Arab patients were 52% of the young and only 12.6% of the old group although total number of Arabs was 35 of 200 patients. No significant difference was found in stage of tumor at diagnosis between the young group (YG) and the old group (OG). Twenty percent of YG had distant metastases compared to 26.5% in the OG. Histopathological grade 3 tumors were found in 33.3% of the YG versus 7.7% in the OG. Surgery and chemotherapy were done in 96% and 88% in YG versus 95.4% and 69.7% in the OG respectively. In a median follow up period of 96 months 35% of young patients died of their disease compared to 33.1% of the old patients. Conclusions: Young patients with colon cancer were diagnosed at the same stage of the disease as old patients. More tumors were high grade in YG. More patients were candidates for chemotherapy in the YG. Significantly more Arab patients were young at the time of diagnosis than Jewish patients. Further studies with higher number of patients are suggested to clarify our findings.